Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmRecruitingPhase 22026-08-04NCT05168163

3 results · Page 1 of 1

Swipe the table sideways for more columns.

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Allegheny General HospitalPittsburghUnited States146
Carle Cancer Center NCI Community Oncology Research ProgramUrbanaUnited States4
Cleveland Clinic Weston FloridaWestonUnited States1
Duke University Medical CenterDurhamUnited States505
Froedtert and the Medical College of Wisconsin LAPSMilwaukeeUnited States1
Mayo Clinic in ArizonaScottsdaleUnited States191
Mayo Clinic in FloridaJacksonvilleUnited States224
Mayo Clinic in RochesterRochesterUnited States687
Medical College of WisconsinMilwaukeeUnited States483
Michigan Cancer Research Consortium NCORPAnn ArborUnited States28
Rapid City Regional HospitalRapid CityUnited States87
Roswell Park Cancer InstituteBuffaloUnited States382
University Hospitals Cleveland Medical CenterClevelandUnited States234
University Medical Center New OrleansNew OrleansUnited States142
University of Chicago Comprehensive Cancer CenterChicagoUnited States273
University of Michigan Comprehensive Cancer CenterAnn ArborUnited States88